Real-world molecular testing, treatment patterns and clinical outcomes in Chinese advanced NSCLC patients, who have progressed on first-line EGFR-TKI therapy (PISCES)

被引：0
|
作者：
Tian, P. [1 ]
Wu, L. [2 ]
Zhou, C. [3 ]
Tan, J. [4 ]
Wang, K. [5 ]
Luo, F. [6 ]
Liu, Y. [7 ]
Guo, Y. [8 ]
Li, Y. [9 ]
Liu, Z. [10 ]
Gong, Y. [11 ]
Wang, Y. [11 ]
Li, W. [12 ]
机构：
[1] Sichuan Univ, Dept Resp & Crit Care Med, West China Sch Med, West China Hosp, Chengdu, Peoples R China
[2] Hunan Canc Hosp, Thorac Med Oncol Dept, Changsha, Peoples R China
[3] Guangzhou Med Univ, Resp Med, State Key Lab Resp Dis, Affiliated Hosp 1, Guangzhou, Peoples R China
[4] Suzhou Municipal Hosp, Oncol, Suzhou Peoples Hosp 4, Suzhou, Peoples R China
[5] Sichuan Univ, Dept Pulm & Crit Care Med, West China Sch Med, West China Hosp, Chengdu, Peoples R China
[6] Sichuan Univ, Oncol, West China Sch Med, West China Hosp, Chengdu, Peoples R China
[7] Sichuan Univ, Thorac Oncol Ward, West China Sch Med, West China Hosp, Chengdu, Peoples R China
[8] Suzhou Municipal Hosp 2 Peoples Hosp, Oncol, Suzhou, Peoples R China
[9] China Med Univ, Dept Oncol, Affiliated Hosp 1, Shenyang, Peoples R China
[10] Capital Med Univ, Beijing Chest Hosp, Oncol, Beijing, Peoples R China
[11] Lung Canc Ctr, Oncol, State Key Lab Biotherapy, Chengdu, Sichuan, Peoples R China
[12] Med & Frontier Sci Ctr Dis Mol Network, Dept Pulm & Crit Care Med, Chengdu, Sichuan, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2374
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1341P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Real-world clinical outcomes in Chinese patients with EGFR-mutated NSCLC progressed from first-line EGFR-TKI: A prospective multicenter study
    Tian, Panwen
    Wu, Lin
    Zhou, Chengzhi
    Tan, Jie
    Wang, Ke
    Luo, Feng
    Liu, Yongmei
    Guo, Yubiao
    Li, Yinyin
    Liu, Zhe
    Gong, Youling
    Wang, Yongsheng
    Li, Weimin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data
    Nieva, Jorge
    Reckamp, Karen L.
    Potter, Danielle
    Taylor, Aliki
    Sun, Ping
    DRUGS-REAL WORLD OUTCOMES, 2022, 9 (03) : 333 - 345
  • [3] Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data
    Jorge Nieva
    Karen L. Reckamp
    Danielle Potter
    Aliki Taylor
    Ping Sun
    Drugs - Real World Outcomes, 2022, 9 : 333 - 345
  • [4] Treatment Patterns and Outcomes of First-line Osimertinib-treated Advanced EGFR Mutated NSCLC Patients: A Real-world Study
    Lee, J. Y.
    Mai, V.
    Garcia, M.
    Cheng, S.
    Khan, K.
    Balaratnam, K.
    Thakral, A.
    Brown, M. C.
    Zhan, L.
    Corke, L.
    Leighl, N.
    Shepherd, F. A.
    Bradbury, P.
    Sacher, A.
    Liu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S440 - S440
  • [5] Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC
    Zhou, C.
    Cheng, Y.
    He, Y.
    Li, W.
    Zhang, H.
    Zhou, Q.
    Wang, B.
    Liu, C.
    Ramalingam, S.
    Walding, A.
    Saggese, M.
    Wang, J.
    Fan, M.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S507 - S508
  • [6] CLINICAL OUTCOMES AFTER FIRST-LINE EGFR-TKI FOR PATIENTS WITH NSCLC, EGFR MUTATION, AND POOR PERFORMANCE STATUS
    Nagamata, Makoto
    Okuma, Yusuke
    Sunami, Kuniko
    Hosomi, Yukio
    Okamura, Tatsuru
    ANNALS OF ONCOLOGY, 2014, 25
  • [7] Real-World Data of Osimertinib in Patients with Metastatic EGFRm plus NSCLC who Progressed on First-Line EGFR TKIs
    Ma, J.
    Tan, S. H.
    Yin, D.
    Tran, A.
    Tan, D.
    Ang, M.
    Takano, A.
    Lim, K. H. T.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Tan, E.
    Lim, D. W.
    Ng, Q. S.
    Tan, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S627 - S628
  • [8] Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC
    Fiala, O.
    Pesek, M.
    Finek, J.
    Benesova, L.
    Bortlicek, Z.
    Minarik, M.
    NEOPLASMA, 2013, 60 (04) : 425 - 431
  • [9] Real-World Outcomes and Treatment Patterns after First-Line Osimertinib in Patients with Advanced NSCLC and Uncommon EGFRm
    Nieva, J.
    Chapaneri, J.
    Lau, Y. K.
    Cooper, M.
    Karia, P. S.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S191 - S191
  • [10] US real-world immunotherapy-based treatment patterns and clinical outcomes of advanced NSCLC (aNSCLC) patients in the first-line setting
    Bittoni, M. A.
    Divan, H. A.
    Krishna, A.
    Gosset, S.
    Carbone, D. P.
    ANNALS OF ONCOLOGY, 2021, 32 : S1416 - S1416
12345